News Fresenius SE & Co. KGaA

Equities

Market Closed - Xetra Other stock markets 11:44:30 2024-04-18 am EDT			After market 12:42:25 pm
26.65 ^EUR	+0.53%		26.59	-0.23%

07:33am	FRESENIUS SE : Gets a Neutral rating from JP Morgan	ZD
Apr. 17	Lauterbach wants to press ahead with hospital reform despite differences	DP

FRESENIUS SE : Gets a Neutral rating from JP Morgan	01:33am	ZD
Lauterbach wants to press ahead with hospital reform despite differences	Apr. 17	DP
State report warns of risks in hospital reform	Apr. 17	DP
FRESENIUS SE : Deutsche Bank maintains a Buy rating	Apr. 17	ZD
Warnings against cutbacks in hospital reform	Apr. 17	DP
Federal and state governments to discuss hospital reform again	Apr. 17	DP
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne, its Third Approved Biosimilar in the U.S.	Apr. 16	AQ
FRESENIUS SE : Gets a Buy rating from Deutsche Bank	Apr. 16	ZD
STOXX 600 nears six-week low on geopolitical jitters; Ericsson shines	Apr. 16	RE
Fresenius at a two-month high - Tyenne launch and fantasy figures	Apr. 16	DP
Fresenius at two-month high - Tyenne launch a milestone	Apr. 16	DP
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
Fresenius : Investor Relations Company Presentation	Apr. 12	PU
Fresenius : Chairman Letter	Apr. 07	PU
Fresenius : MAbxience and Teva announce strategic global license agreement for biosimilar oncology treatment	Apr. 04	PU
Fresenius : Management Board buys own shares	Apr. 04	PU
DD: Fresenius SE & Co. KGaA: Robert Möller, buy	Apr. 04	EQ
DD: Fresenius SE & Co. KGaA: Sara Hennicken, buy	Apr. 04	EQ
DD: Fresenius SE & Co. KGaA: Pierluigi Antonelli, buy	Apr. 04	EQ
DD: Fresenius SE & Co. KGaA: Michael Sen, buy	Apr. 04	EQ

No results for this search

FRESENIUS : A good ending does not allow for extreme optimism in 2024

February 22, 2024 at 07:42 am EST